For decades, hepatitis C was a disease with no cure and a grim prognosis — but that changed dramatically with the advent of direct-acting antiviral medications, which now cure over 95% of infected patients. Despite this breakthrough, an estimated 2.4 million Americans are still living with chronic hepatitis C, and nearly half do not know they are infected, according to the CDC. The virus silently damages the liver over years, causing cirrhosis and liver cancer in a significant proportion of those who go untreated. Finding the infected, linking them to care, and curing them is now the central challenge — the medical tools exist, but the public health implementation lags behind. This guide explains who should be tested, what treatment looks like today, and why acting early matters. For related conditions, see our medical conditions guide.
What Is Hepatitis C?
Hepatitis C is a blood-borne viral infection caused by the hepatitis C virus (HCV), an RNA virus belonging to the Flaviviridae family. There are six major genotypes (and multiple subtypes) of HCV, which differ in their geographic distribution and, historically, in their response to treatment — though modern pangenotypic medications are effective against all genotypes. Genotype 1 is the most common in the United States, accounting for approximately 70% of infections.
Upon initial infection, HCV enters the liver cells and hijacks the cellular machinery to replicate. The immune system mounts a response, but HCV is remarkably adept at evading it — the virus mutates rapidly, producing a swarm of closely related variants (quasispecies) that stay ahead of immune recognition. As a result, approximately 75-85% of acutely infected individuals fail to clear the virus and develop chronic infection. Unlike hepatitis B, there is no vaccine for hepatitis C.
Chronic HCV infection causes progressive liver inflammation and fibrosis. Over 20-30 years, approximately 15-30% of chronically infected patients develop cirrhosis. Once cirrhosis is established, the annual risk of hepatocellular carcinoma (HCC) is 1-4%, and the risk of decompensated liver failure (ascites, variceal bleeding, hepatic encephalopathy) is 3-6%. According to the WHO, hepatitis C causes approximately 400,000 deaths globally each year.
How Hepatitis C Is Transmitted
Hepatitis C is primarily transmitted through direct blood-to-blood contact. The most common route of transmission in the United States today is sharing of needles, syringes, and other equipment used to inject drugs. The opioid epidemic has driven a sharp increase in new HCV infections among young people who inject drugs — new infections nearly tripled between 2010 and 2020.
Before widespread blood supply screening began in 1992, blood transfusions and organ transplants were significant sources of infection. Anyone who received a blood transfusion, blood components, or an organ transplant before July 1992 should be tested for HCV. Healthcare-related transmission through needlestick injuries occurs but is uncommon, with a seroconversion rate of approximately 1.8% after a needlestick from an HCV-positive source.
Other, less common routes include perinatal transmission (mother-to-child, occurring in approximately 6% of pregnancies with viremic mothers), sexual transmission (risk is low in monogamous heterosexual relationships but higher among men who have sex with men, particularly those with HIV co-infection), tattoos or piercings with unsterile equipment, and sharing of personal items like razors or toothbrushes. Hepatitis C is not spread through casual contact, kissing, hugging, sharing food or water, or breastfeeding.
Symptoms
Acute hepatitis C infection is usually asymptomatic — only about 20-30% of newly infected individuals develop symptoms. When symptoms occur, they typically appear 2-12 weeks after exposure and may include fatigue, nausea, loss of appetite, abdominal pain, dark urine, and jaundice. Because most acute infections are asymptomatic, the majority of new infections go undiagnosed.
Chronic hepatitis C can remain asymptomatic for decades. Some patients experience nonspecific symptoms like fatigue, brain fog, joint pain, and depression long before liver disease becomes clinically apparent. These extrahepatic manifestations of HCV are increasingly recognized and may include mixed cryoglobulinemia (which can cause vasculitis, purpura, and kidney disease), glomerulonephritis, porphyria cutanea tarda, and non-Hodgkin lymphoma.
When symptoms of advanced liver disease develop — jaundice, ascites, variceal bleeding, confusion, easy bruising — cirrhosis has typically already been established for years. This long asymptomatic phase is exactly why screening and early detection are so critical. By the time symptoms prompt a patient to seek care, the window for preventing liver damage has often closed.
Who Should Be Tested
In 2020, the CDC expanded its screening recommendations to include all adults aged 18 and older at least once in their lifetime — a universal screening approach replacing the previous risk-based strategy. The USPSTF made a similar Grade B recommendation for universal screening. Screening during each pregnancy is also recommended.
People at higher risk who should be tested regardless of age include:
- Current or former injection drug users (even if only once)
- Recipients of blood transfusions or organ transplants before July 1992
- People with HIV
- Children born to HCV-positive mothers
- People with unexplained liver disease or elevated liver enzymes
- Healthcare workers after needlestick exposure
- People who have been incarcerated
- People on long-term hemodialysis
Testing begins with an HCV antibody test, which detects whether you have ever been exposed to the virus. A positive antibody test requires confirmation with an HCV RNA test (viral load), which determines whether the virus is currently present. A positive antibody with a negative RNA test indicates a past infection that has been cleared (either spontaneously or through treatment). A positive RNA test confirms active infection requiring treatment.
The Revolution in Treatment
The development of direct-acting antiviral (DAA) medications represents one of the most significant advances in the history of medicine. Before DAAs, the standard treatment was pegylated interferon and ribavirin — a regimen that lasted 24-48 weeks, cured only 40-60% of patients (depending on genotype), and caused severe side effects including flu-like symptoms, anemia, depression, and thyroid disorders.
Today’s DAA regimens cure over 95% of patients in as little as 8-12 weeks with minimal side effects. DAAs work by directly targeting specific proteins essential for HCV replication. Different classes of DAAs target different viral proteins: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors. Modern regimens combine two or three of these classes for maximal efficacy.
The most commonly used pangenotypic regimens include sofosbuvir/velpatasvir (Epclusa) — effective against all genotypes in a single daily pill for 12 weeks — and glecaprevir/pibrentasvir (Mavyret), which treats all genotypes and can be completed in as few as 8 weeks for treatment-naive patients without cirrhosis. According to the AASLD/IDSA HCV Guidelines, the choice of regimen depends on genotype, prior treatment history, presence of cirrhosis, and renal function.
What Treatment Is Like
Treatment with DAAs is remarkably straightforward compared to the interferon era. You take one or two pills daily for 8-12 weeks (or 16 weeks in some cases of advanced disease). Side effects are generally mild — the most common include headache, fatigue, and nausea — and most patients complete treatment without interruption.
Before starting treatment, your provider will assess your HCV genotype, viral load, degree of liver fibrosis (using non-invasive methods like FibroScan elastography or the FIB-4 index), kidney function, and other medications to check for drug interactions. For patients with decompensated cirrhosis (Child-Pugh B or C), treatment selection is more complex because protease inhibitor-containing regimens are contraindicated, and these patients may require liver transplant evaluation in addition to antiviral therapy.
A sustained virologic response (SVR) — defined as undetectable HCV RNA 12 weeks after completing treatment — is considered a cure. SVR rates with current regimens consistently exceed 95%, even in previously “difficult to treat” populations including patients with cirrhosis, prior treatment failure, and HIV co-infection. After achieving SVR, reinfection is possible (there is no protective immunity), so ongoing risk reduction is important for people with continuing exposure risks.
Cost was initially a major barrier — the first DAA, sofosbuvir (Sovaldi), was priced at $84,000 per course. Competition among manufacturers and the availability of generic formulations have significantly reduced costs, and most insurance plans, including Medicaid, now cover DAA therapy. Understanding the financial landscape of hepatitis C treatment and available assistance programs can help overcome remaining barriers.
After the Cure: What to Know
Achieving SVR (cure) dramatically improves outcomes. Cured patients have a 70% reduction in all-cause mortality and a significant reduction in liver-related complications. Liver fibrosis often regresses after cure, and the risk of liver cancer decreases substantially — though it does not return to zero, particularly in patients who had cirrhosis before treatment.
Patients who had advanced fibrosis or cirrhosis before achieving SVR require lifelong liver cancer surveillance with ultrasound every six months. The AASLD guidelines are clear on this point: cure does not eliminate the need for HCC screening in patients with significant pre-existing fibrosis. Patients without advanced fibrosis generally do not need ongoing HCC surveillance after cure.
Other post-cure considerations include management of comorbidities (diabetes, cardiovascular disease, and kidney disease associated with HCV may persist after cure), monitoring for reinfection in patients with ongoing risk behaviors, and psychological adjustment. Many patients experience a mix of relief and anxiety after a long-standing diagnosis is resolved, and support from patient advocacy organizations can be valuable.
Hepatitis C and Special Populations
People who inject drugs (PWID) are the population most affected by hepatitis C and face the greatest barriers to diagnosis and treatment. Historically, many providers and insurers required sobriety before authorizing treatment, but this restriction has been largely abandoned. Current guidelines recommend treatment for all patients with chronic hepatitis C, including active injection drug users, without sobriety requirements. Treatment in this population achieves SVR rates comparable to other patients, and treatment is also a prevention strategy — curing infected individuals reduces the reservoir of virus available to infect others.
Patients with HIV co-infection have higher rates of liver fibrosis progression and should be prioritized for treatment. DAA regimens are highly effective in co-infected patients, though drug interactions between DAAs and antiretroviral medications must be carefully evaluated. Patients with chronic kidney disease, including those on hemodialysis, can be safely treated with specific regimens (glecaprevir/pibrentasvir is the preferred option for severe renal impairment).
Pregnant women with HCV are not currently treated during pregnancy, as DAA safety in pregnancy has not been established, though clinical trials are underway. All pregnant women should be screened, and infants born to HCV-positive mothers should be tested after 18 months of age (or with HCV RNA testing at 2 months if earlier diagnosis is desired).
Frequently Asked Questions
Is hepatitis C always curable now?
With currently available DAA therapy, over 95% of patients with chronic hepatitis C are cured after 8-12 weeks of treatment. Even patients with cirrhosis, prior treatment failure, and HIV co-infection achieve cure rates above 90%. A small percentage of patients may not respond to initial therapy but can often be successfully retreated with alternative regimens. True treatment failure is now very rare.
Can you get hepatitis C more than once?
Yes. Unlike hepatitis A and B, infection with hepatitis C does not produce lasting protective immunity. If you have been cured of hepatitis C and are re-exposed (for example, through continued injection drug use), you can become reinfected. Reinfection requires new treatment. This is also why developing a hepatitis C vaccine has proven so challenging.
How long can you have hepatitis C without knowing?
You can carry chronic hepatitis C for decades without symptoms. Many patients are diagnosed only when routine blood work reveals elevated liver enzymes, or when complications of advanced liver disease develop. This is why universal screening is so important — the majority of people with chronic hepatitis C had no idea they were infected until they were tested.
Is hepatitis C an STD?
Hepatitis C can be transmitted sexually, but it is far less efficient as a sexually transmitted infection than hepatitis B or HIV. The risk of sexual transmission is low in monogamous heterosexual couples — approximately 1 in 190,000 sexual contacts. Risk is higher among men who have sex with men, particularly those with HIV co-infection or those who engage in practices that involve potential blood exposure. The primary route of transmission remains blood-to-blood contact, most commonly through injection drug use.
Will my liver heal after hepatitis C is cured?
Liver fibrosis often improves (regresses) after achieving cure, particularly in patients with mild to moderate fibrosis. Even patients with early cirrhosis may experience some degree of fibrosis regression. However, patients with established cirrhosis — especially decompensated cirrhosis — may have irreversible liver damage, and some may still require liver transplantation despite viral cure. This is why early treatment, before advanced fibrosis develops, produces the best outcomes.
Getting Tested and Getting Treated
If you were born between 1945 and 1965, have ever injected drugs, received a blood transfusion before 1992, or simply have never been tested, get tested for hepatitis C. It is a simple blood test that can detect a curable disease. If you test positive, know that treatment is short (8-12 weeks), highly effective (over 95% cure rate), well-tolerated, and increasingly accessible.
Do not let stigma, cost concerns, or past barriers prevent you from seeking treatment. The landscape has changed dramatically — sobriety requirements have been removed in most states, insurance coverage has expanded, and generic options have reduced costs. Hepatitis C is now a curable disease, and every person cured is one fewer source of transmission. The tools to eliminate hepatitis C exist. The only missing piece is making sure everyone who needs testing and treatment actually receives it.